Spontaneous nasal perforation in a bevacizumab-treated patient with metastatic breast cancer

被引：4
|
作者：
Rodriguez, Cesar A. [1 ]
Martin, Teresa [1 ]
Lozano, Rebeca [1 ]
Gomez, Amalia [1 ]
Cruz, Juan J. [1 ]
机构：
[1] Hosp Univ Salamanca IBSAL, Dept Med Oncol, Salamanca, Spain
来源：
BREAST JOURNAL | 2017年 / 23卷 / 06期
关键词：
bevacizumab; breast cancer; nasal septum perforation; SEPTUM PERFORATION; PACLITAXEL; THERAPY; TRIAL;
D O I：
10.1111/tbj.12913
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Nasal septum perforation in patients with cancer receiving systemic therapy is rare, and its association with bevacizumab use has described recently in the literature. Here, we report the case of a 34-year-old woman with hormone-sensitive, HER-2/neu negative, metastatic breast cancer who develope a nasal septum perforation during the treatment with paclitaxel and bevacizumab.
引用
收藏
页码：745 / 746
页数：2
相关论文
共 50 条
  • [21] CHRONIC EMPYEMA IN A PATIENT WITH METASTATIC BREAST CANCER ON BEVACIZUMAB TREATMENT
    Yoshimura, Noriko
    Kawabuchi, Yoshiharu
    Kondo, Tomohiro
    ANNALS OF ONCOLOGY, 2014, 25
  • [22] VEGF-A levels in bevacizumab-treated breast cancer patients: a systematic review and meta-analysis
    Lucas Vieira dos Santos
    Marcelo Rocha Cruz
    Gilberto de Lima Lopes
    Joao Paulo da Silveira Nogueira Lima
    Breast Cancer Research and Treatment, 2015, 151 : 481 - 489
  • [23] VEGF-A levels in bevacizumab-treated breast cancer patients: a systematic review and meta-analysis
    dos Santos, Lucas Vieira
    Cruz, Marcelo Rocha
    Lopes, Gilberto de Lima
    da Silveira Nogueira Lima, Joao Paulo
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 151 (03) : 481 - 489
  • [24] VEGFR-1 polymorphisms as potential predictors of clinical outcome in bevacizumab-treated patients with metastatic pancreatic cancer
    Lambrechts, D.
    Delmar, P.
    Buysschaert, I.
    Claes, B.
    Yesilyurt, B. T.
    Verslype, C.
    Foernzler, D.
    Carmeliet, P.
    Scherer, S.
    Van Cutsem, E.
    EJC SUPPLEMENTS, 2009, 7 (03): : 10 - 10
  • [25] Intestinal Perforation due to Neutropenic Enterocolitis in a Patient Treated with Bevacizumab for Ovarian Cancer
    Sasaki, Akinori
    Harano, Kenichi
    Kogawa, Takahiro
    Matsubara, Nobuaki
    Naito, Yoichi
    Hosono, Ako
    Mukai, Hirofumi
    Yoshino, Takayuki
    Mukohara, Toru
    CASE REPORTS IN ONCOLOGICAL MEDICINE, 2020, 2020
  • [26] Fatal hemoptysis in a patient with breast cancer treated with bevacizumab and paclitaxel
    Philippin-Lauridant, G.
    Thureau, S.
    Ouvrier, M. -J.
    Blot, E.
    ANNALS OF ONCOLOGY, 2008, 19 (11) : 1977 - U10
  • [27] Gastrointestinal perforation associated with bevacizumab in metastatic colorectal cancer
    Fang, Kunpeng
    Wang, Jie
    Yuan, Jianyong
    Sui, Chengjun
    Zhi, Jiajun
    Xia, Yong
    Sun, Minmin
    CANCER REPORTS, 2024, 7 (02)
  • [28] Perforation of the Nasal Septum in a Colorectal Cancer Patient Treated With Aflibercept: A Case Report
    Fuentes, Javier David Benitez
    Lorenzo, Alfonso Lopez de Sa
    Elias, Alberto Elpidio Calvo
    Rojas, Carmen Toledano
    Ortega, Monica Granja
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (07)
  • [29] Association of antibiotic exposure with the mortality in bevacizumab-treated metastatic colorectal cancer: A secondary analysis from Dryad database.
    Sun, Chenyu
    Guo, Xianwei
    Kozma, Kelly
    Bhan, Chandur
    Kim, Na Hyun
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [30] NOTCH AND DLL4 EXPRESSION IN BEVACIZUMAB-TREATED COLON CANCER PATIENTS
    Negri, F. V.
    Bozzetti, C.
    Crafa, P.
    Pedrazzi, G.
    Porzio, R.
    Gardini, G.
    Tamagnini, I.
    Cavanna, L.
    Paties, C.
    Ardizzoni, A.
    ANNALS OF ONCOLOGY, 2012, 23 : 216 - 217
12345